Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point

Cell Reports

Volumn 13, Issue 5, 2015, Pages 1033-1045

  Darman, Rachel B ^a   Seiler, Michael ^a   Agrawal, Anant A ^a   Lim, Kian H ^a   Peng, Shouyong ^a   Aird, Daniel ^a   Bailey, Suzanna L ^a   Bhavsar, Erica B ^b   Chan, Betty ^a   Colla, Simona ^c   Corson, Laura ^a   Feala, Jacob ^a   Fekkes, Peter ^a   Ichikawa, Kana ^a   Keaney, Gregg F ^a   Lee, Linda ^a   Kumar, Pavan ^a   Kunii, Kaiko ^a   MacKenzie, Crystal ^a   Matijevic, Mark ^a   Mizui, Yoshiharu ^a   Myint, Khin ^a   Park, Eun Sun ^a   Puyang, Xiaoling ^a   Selvaraj, Anand ^a   Thomas, Michael P ^a   Tsai, Jennifer ^a   Wang, John Y ^a   Warmuth, Markus ^a   Yang, Hui ^c   Zhu, Ping ^a   Garcia Manero, Guillermo ^c   Furman, Richard R ^b   Yu, Lihua ^a   Smith, Peter G ^a   Buonamici, Silvia ^a   more..

^a EISAI INC   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PHOSPHOPROTEIN; RNA SPLICING FACTOR; SF3B1 PROTEIN, HUMAN; SMALL NUCLEAR RIBONUCLEOPROTEIN;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE MUTATION; GENETIC TRANSCRIPTION; MALIGNANT NEOPLASTIC DISEASE; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; NONSENSE MEDIATED MRNA DECAY; PRIORITY JOURNAL; RNA SPLICING; SEQUENCE ANALYSIS; SF3B1 GENE; WILD TYPE; ALLELE; AMINO ACID SEQUENCE; CHEMISTRY; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; MOLECULAR GENETICS; MUTATION; MUTATION RATE; NEOPLASM; NUCLEOTIDE SEQUENCE;

ALLELES; ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; BASE SEQUENCE; HEK293 CELLS; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; MUTATION RATE; NEOPLASMS; NONSENSE MEDIATED MRNA DECAY; PHOSPHOPROTEINS; RIBONUCLEOPROTEIN, U2 SMALL NUCLEAR; RNA SPLICING FACTORS;

EID: 84947417142     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.09.053     Document Type: Article

References (46)

1. Allikmets R., Raskind W.H., Hutchinson A., Schueck N.D., Dean M., Koeller D.M. Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A). Hum. Mol. Genet. 1999, 8:743-749.
2. Biankin A.V., Waddell N., Kassahn K.S., Gingras M.C., Muthuswamy L.B., Johns A.L., Miller D.K., Wilson P.J., Patch A.M., Wu J., et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012, 491:399-405. Australian Pancreatic Cancer Genome Initiative.
3. Boultwood J., Pellagatti A., Nikpour M., Pushkaran B., Fidler C., Cattan H., Littlewood T.J., Malcovati L., Della Porta M.G., Jädersten M., et al. The role of the iron transporter ABCB7 in refractory anemia with ring sideroblasts. PLoS ONE 2008, 3:e1970.
4. Chua K., Reed R. Human step II splicing factor hSlu7 functions in restructuring the spliceosome between the catalytic steps of splicing. Genes Dev. 1999, 13:841-850.
5. Chua K., Reed R. The RNA splicing factor hSlu7 is required for correct 3' splice-site choice. Nature 1999, 402:207-210.
6. Coolidge C.J., Seely R.J., Patton J.G. Functional analysis of the polypyrimidine tract in pre-mRNA splicing. Nucleic Acids Res. 1997, 25:888-896.
7. Corrionero A., Miñana B., Valcárcel J. Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. Genes Dev. 2011, 25:445-459.
8. Corsini L., Bonnal S., Basquin J., Hothorn M., Scheffzek K., Valcárcel J., Sattler M. U2AF-homology motif interactions are required for alternative splicing regulation by SPF45. Nat. Struct. Mol. Biol. 2007, 14:620-629.
9. de Almeida S.F., Grosso A.R., Koch F., Fenouil R., Carvalho S., Andrade J., Levezinho H., Gut M., Eick D., Gut I., et al. Splicing enhances recruitment of methyltransferase HYPB/Setd2 and methylation of histone H3 Lys36. Nat. Struct. Mol. Biol. 2011, 18:977-983.
10. DeBoever C., Ghia E.M., Shepard P.J., Rassenti L., Barrett C.L., Jepsen K., Jamieson C.H., Carson D., Kipps T.J., Frazer K.A. Transcriptome sequencing reveals potential mechanism of cryptic 3' splice site selection in SF3B1-mutated cancers. PLoS Comput. Biol. 2015, 11:e1004105.
11. Dehm S.M. mRNA splicing variants: exploiting modularity to outwit cancer therapy. Cancer Res. 2013, 73:5309-5314.
12. Ebert B.L., Pretz J., Bosco J., Chang C.Y., Tamayo P., Galili N., Raza A., Root D.E., Attar E., Ellis S.R., Golub T.R. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008, 451:335-339.
13. Ellis M.J., Ding L., Shen D., Luo J., Suman V.J., Wallis J.W., Van Tine B.A., Hoog J., Goiffon R.J., Goldstein T.C., et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012, 486:353-360.
14. Furney S.J., Pedersen M., Gentien D., Dumont A.G., Rapinat A., Desjardins L., Turajlic S., Piperno-Neumann S., de la Grange P., Roman-Roman S., et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. 2013, 3:1122-1129.
15. Ge Y., Porse B.T. The functional consequences of intron retention: alternative splicing coupled to NMD as a regulator of gene expression. BioEssays 2014, 36:236-243.
16. Gentien D., Kosmider O., Nguyen-Khac F., Albaud B., Rapinat A., Dumont A.G., Damm F., Popova T., Marais R., Fontenay M., et al. A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages. Leukemia 2014, 28:1355-1357.
17. Golas M.M., Sander B., Will C.L., Lührmann R., Stark H. Molecular architecture of the multiprotein splicing factor SF3b. Science 2003, 300:980-984.
18. Gozani O., Potashkin J., Reed R. A potential role for U2AF-SAP 155 interactions in recruiting U2 snRNP to the branch site. Mol. Cell. Biol. 1998, 18:4752-4760.
19. Harbour J.W., Roberson E.D., Anbunathan H., Onken M.D., Worley L.A., Bowcock A.M. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat. Genet. 2013, 45:133-135.
20. Horowitz D.S. The mechanism of the second step of pre-mRNA splicing. Wiley Interdiscip. Rev. RNA 2012, 3:331-350.
21. Ilagan J.O., Ramakrishnan A., Hayes B., Murphy M.E., Zebari A.S., Bradley P., Bradley R.K. U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res. 2015, 25:14-26.
22. Kalyna M., Simpson C.G., Syed N.H., Lewandowska D., Marquez Y., Kusenda B., Marshall J., Fuller J., Cardle L., McNicol J., et al. Alternative splicing and nonsense-mediated decay modulate expression of important regulatory genes in Arabidopsis. Nucleic Acids Res. 2012, 40:2454-2469.
23. Kervestin S., Jacobson A. NMD: a multifaceted response to premature translational termination. Nat. Rev. Mol. Cell Biol. 2012, 13:700-712.
24. Kfir N., Lev-Maor G., Glaich O., Alajem A., Datta A., Sze S.K., Meshorer E., Ast G. SF3B1 association with chromatin determines splicing outcomes. Cell Rep. 2015, 11:618-629.
25. Khan S.N., Jankowska A.M., Mahfouz R., Dunbar A.J., Sugimoto Y., Hosono N., Hu Z., Cheriyath V., Vatolin S., Przychodzen B., et al. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia 2013, 27:1301-1309.
26. Kim E., Ilagan J.O., Liang Y., Daubner G.M., Lee S.C., Ramakrishnan A., Li Y., Chung Y.R., Micol J.B., Murphy M.E., et al. SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. Cancer Cell 2015, 27:617-630.
27. Kong Y., Krauthammer M., Halaban R. Rare SF3B1 R625 mutations in cutaneous melanoma. Melanoma Res. 2014, 24:332-334.
28. Lallena M.J., Chalmers K.J., Llamazares S., Lamond A.I., Valcárcel J. Splicing regulation at the second catalytic step by Sex-lethal involves 3' splice site recognition by SPF45. Cell 2002, 109:285-296.
29. Landau D.A., Carter S.L., Stojanov P., McKenna A., Stevenson K., Lawrence M.S., Sougnez C., Stewart C., Sivachenko A., Wang L., et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013, 152:714-726.
30. Lim K.H., Ferraris L., Filloux M.E., Raphael B.J., Fairbrother W.G. Using positional distribution to identify splicing elements and predict pre-mRNA processing defects in human genes. Proc. Natl. Acad. Sci. USA 2011, 108:11093-11098.
31. Malcovati L., Karimi M., Papaemmanuil E., Ambaglio I., Jädersten M., Jansson M., Elena C., Gallì A., Walldin G., Della Porta M.G., et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood 2015, 126:233-241.
32. Matera A.G., Wang Z. A day in the life of the spliceosome. Nat. Rev. Mol. Cell Biol. 2014, 15:108-121.
33. Mercer T.R., Clark M.B., Andersen S.B., Brunck M.E., Haerty W., Crawford J., Taft R.J., Nielsen L.K., Dinger M.E., Mattick J.S. Genome-wide discovery of human splicing branchpoints. Genome Res. 2015, 25:290-303.
34. Oda Y., Huang K., Cross F.R., Cowburn D., Chait B.T. Accurate quantitation of protein expression and site-specific phosphorylation. Proc. Natl. Acad. Sci. USA 1999, 96:6591-6596.
35. Papaemmanuil E., Cazzola M., Boultwood J., Malcovati L., Vyas P., Bowen D., Pellagatti A., Wainscoat J.S., Hellstrom-Lindberg E., Gambacorti-Passerini C., et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N. Engl. J. Med. 2011, 365:1384-1395. Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium.
36. Rivas M.A., Pirinen M., Conrad D.F., Lek M., Tsang E.K., Karczewski K.J., Maller J.B., Kukurba K.R., DeLuca D.S., Fromer M., et al. Human genomics. Effect of predicted protein-truncating genetic variants on the human transcriptome. Science 2015, 348:666-669. GTEx Consortium, Geuvadis ConsortiumGeuvadis Consortium.
37. Schneider R.K., Ademà V., Heckl D., Järås M., Mallo M., Lord A.M., Chu L.P., McConkey M.E., Kramann R., Mullally A., et al. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell 2014, 26:509-520.
38. Shirai C.L., Ley J.N., White B.S., Kim S., Tibbitts J., Shao J., Ndonwi M., Wadugu B., Duncavage E.J., Okeyo-Owuor T., et al. Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo. Cancer Cell 2015, 27:631-643.
39. Singh R.K., Cooper T.A. Pre-mRNA splicing in disease and therapeutics. Trends Mol. Med. 2012, 18:472-482.
40. Singh G., Kucukural A., Cenik C., Leszyk J.D., Shaffer S.A., Weng Z., Moore M.J. The cellular EJC interactome reveals higher-order mRNP structure and an EJC-SR protein nexus. Cell 2012, 151:750-764.
41. van Anken E., Pena F., Hafkemeijer N., Christis C., Romijn E.P., Grauschopf U., Oorschot V.M., Pertel T., Engels S., Ora A., et al. Efficient IgM assembly and secretion require the plasma cell induced endoplasmic reticulum protein pERp1. Proc. Natl. Acad. Sci. USA 2009, 106:17019-17024.
42. Wahl M.C., Will C.L., Lührmann R. The spliceosome: design principles of a dynamic RNP machine. Cell 2009, 136:701-718.
43. Yoshida K., Ogawa S. Splicing factor mutations and cancer. Wiley Interdiscip. Rev. RNA 2014, 5:445-459.
44. Yoshida K., Sanada M., Shiraishi Y., Nowak D., Nagata Y., Yamamoto R., Sato Y., Sato-Otsubo A., Kon A., Nagasaki M., et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011, 478:64-69.
45. Zhang J., Manley J.L. Misregulation of pre-mRNA alternative splicing in cancer. Cancer Discov. 2013, 3:1228-1237.
46. Zhou Q., Derti A., Ruddy D., Rakiec D., Kao I., Lira M., Gibaja V., Chan H., Yang Y., Min J., et al. A chemical genetics approach for the functional assessment of novel cancer genes. Cancer Res. 2015, 75:1949-1958.